Medicare's first drug ne­go­ti­a­tion list like­ly to fu­el pub­lic pric­ing dis­cus­sions for phar­ma mar­keters

Who’s on the list? That’s the ques­tion many in the phar­ma in­dus­try are ask­ing to­day about CMS re­leas­ing the names of the first 10 drugs, which will have their prices ne­go­ti­at­ed un­der the In­fla­tion Re­duc­tion Act.

The list, pub­lished Tues­day, is led by Bris­tol My­ers’ Eliquis, Eli Lil­ly’s Jar­diance, John­son & John­son’s Xarel­to, Mer­ck’s Janu­via and As­traZeneca’s Farx­i­ga. It in­cludes many of the most-used Medicare drugs to treat chron­ic con­di­tions. And that’s an im­por­tant point for mar­keters to make.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER